318 related articles for article (PubMed ID: 23618374)
1. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.
Park SJ; Sawitzki B; Kluwe L; Mautner VF; Holtkamp N; Kurtz A
BMC Med; 2013 Apr; 11():109. PubMed ID: 23618374
[TBL] [Abstract][Full Text] [Related]
2. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
4. Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis.
Weng Y; Chen Y; Chen J; Liu Y; Bao T
Med Oncol; 2013 Jun; 30(2):531. PubMed ID: 23483452
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
[TBL] [Abstract][Full Text] [Related]
6. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich RE; Hartmann M; Mautner VF
Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
[TBL] [Abstract][Full Text] [Related]
7. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
9. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Nguyen R; Jett K; Harris GJ; Cai W; Friedman JM; Mautner VF
J Neurooncol; 2014 Jan; 116(2):307-13. PubMed ID: 24166582
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Jones J; Cain S; Pesic-Smith J; Choong PFM; Morokoff AP; Drummond KJ; Dabscheck G
J Neurooncol; 2021 Sep; 154(3):265-274. PubMed ID: 34529228
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
Friedrich RE; Keiner D; Hagel C
Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826
[TBL] [Abstract][Full Text] [Related]
12. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.
Hummel TR; Jessen WJ; Miller SJ; Kluwe L; Mautner VF; Wallace MR; Lázaro C; Page GP; Worley PF; Aronow BJ; Schorry EK; Ratner N
Clin Cancer Res; 2010 Oct; 16(20):5048-57. PubMed ID: 20739432
[TBL] [Abstract][Full Text] [Related]
13. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
14. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
Salamon J; Mautner VF; Adam G; Derlin T
Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
[TBL] [Abstract][Full Text] [Related]
15. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1.
McCaughan JA; Holloway SM; Davidson R; Lam WW
J Med Genet; 2007 Jul; 44(7):463-6. PubMed ID: 17327286
[TBL] [Abstract][Full Text] [Related]
16. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
[TBL] [Abstract][Full Text] [Related]
17. Malignant peripheral nerve sheath tumor on a patient with a maternally inherited novel NF1 gene pathogenic germline variant: Case report.
Moreno-Salgado R; Rios-Lozano YZ; Tamayo-Palacio AC; Castillo AI; Hidalgo-Martínez MF
Cancer Genet; 2023 Jun; 274-275():72-74. PubMed ID: 37087941
[TBL] [Abstract][Full Text] [Related]
18. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
Ferner RE; Gutmann DH
Cancer Res; 2002 Mar; 62(5):1573-7. PubMed ID: 11894862
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.
Zhou H; Coffin CM; Perkins SL; Tripp SR; Liew M; Viskochil DH
Am J Surg Pathol; 2003 Oct; 27(10):1337-45. PubMed ID: 14508395
[TBL] [Abstract][Full Text] [Related]
20. Malignant peripheral nerve sheath tumors in neurofibromatosis 1.
King AA; Debaun MR; Riccardi VM; Gutmann DH
Am J Med Genet; 2000 Aug; 93(5):388-92. PubMed ID: 10951462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
